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The objective of this study was to compare the effect
of an angiotensin-converting enzyme (ACE) inhibitor and
a calcium channel blocker on the development of renal
changes in diabetic rats. Diabetes was induced by an in-
travenous injection of streptozotocin in normotensive Wis-
tar rats. Treatment was commenced immediately in 1 set of
rats with 4 treatment arms: nitrendipine (250 mg/kg fod-
der), enalapril (35 mg/L drinking water), both treatments
in combination, or placebo. Treatment was continued for 9
weeks. Another set of rats was left with untreated diabetes
for3monthsfollowedby7weekstreatmentasabove.When
starting treatment right after induction of diabetes, ni-
trendipine signiﬁcantly reduced urinary albumin excretion
(UAE) to the nondiabetic level (P <. 05) without reducing
bloodpressure(BP),whereasenalaprilfailedtosigniﬁcantly
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reduce UAE despite a reduction in BP. Combining the
two treatments showed no further reduction in UAE com-
pared to monotherapy with nitrendipine, despite a lower
BP.Whenleavingdiabeticratsuntreatedfor3months,only
the coadministration of nitrendipine and enalapril showed
a signiﬁcant reduction in UAE compared to monotherapy
and placebo treatment, but showed no signiﬁcant effect
on BP.
Keywords Diabetes; Enalapril; Nitrendipiner; Rats; Renal Hyper-
trophy; Urinary Albumin Excretion
Diabeticnephropathyisthemostcommoncauseofendstage
renal failure (ESRD) in the Western world [1], and is charac-
terized by persistent proteinuria, hypertension, and declining
renal function. Good metabolic control is essential in the pre-
vention of diabetic nephropathy [2], but the treatment of hyper-
tension with angiotensin-converting enzyme (ACE) inhibitors
(ACEIs) has also proven effective in preventing or postponing
the development of diabetic kidney disease [3–5]. The supe-
rior effect of ACEIs compared to conventional antihyperten-
sive treatment with β-blockers and diuretics seems to be due
to a renoprotective effect, i.e., a renal effect beyond the blood
pressure(BP)-loweringeffect [6–9].However,other antihyper-
tensive drugs, such as calcium channel blockers (CCBs), may
also be effective in the treatment of diabetic kidney disease, al-
though controversy still exists whether dihydropyridine CCBs
and nondihydropyridine CCBs are equally effective in type 1
and type 2 diabetes mellitus [10–14]. In previous studies of
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experimentallydiabeticrats,weshowedthattreatmentwiththe
dihydropyridine CCB nitrendipine was able to reduce urinary
albumin excretion (UAE) and renal and glomerular hypertro-
phy when starting treatment early in the disease [15, 16]. In the
present study, we compared the effect of the dihydropyridine
CCB nitrendipine and the ACEI enalapril on renal changes in
experimental diabetes in rats, focusing on UAE and renal and
glomerular hypertrophy. The importance of the timing of inter-
vention was investigated as well as a possible additive effect by
combined treatment with CCB and ACEI. This study is the ﬁrst
to report the effect of combination therapy with a dihydropyri-
dine CCB and an ACEI in a model of type 1 diabetes.
MATERIAL AND METHODS
Animals
One hundred and ﬁfty-seven adult female Wistar rats
(Møllegaards Avlslab, Eiby, Denmark), with an initial mean
body weight of 200 ± 1 g, were randomized into 5 groups:
nondiabeticplacebo-treatedcontrolrats(CP),diabeticplacebo-
treated rats (DP), diabetic nitrendipine-treated rats (DN), dia-
betic enalapril-treated rats (DE), and diabetic nitrendipine- and
enalapril-treated rats (DNE). All animal groups were assigned
to 1 of 2 intervention trials: prevention with any of the antihy-
pertensive treatment regimens starting at the time of diabetes
induction and animals were killed after 9 weeks; intervention,
leaving animals with untreated diabetes for 3 months followed
by 7 weeks treatment. Diabetes was induced by a single intra-
venous (IV) injection of streptozotocin (STZ) (50 mg/kg body
weight) (Upjohn Company, Kalamazoo, Michigan, USA) fol-
lowing 12 hours’ overnight fasting. Animals were housed 2
to 3 animals per cage in a room with 12:12 hours’ artiﬁcial
light cycle, mean room temperature 21◦C ± 2◦C, and humid-
ity 55% ± 2%. All principles of laboratory animal care and
the current version of the Danish Law on Animal Experiments
were followed. Nitrendipine (Bayer Company, Germany) was
administered in the diet at a concentration of 250 mg/kg [15,
17],whereasenalapril(enalaprilmaleate;SigmaChemicals,St.
Louis,Missouri,USA)wasgivenindrinkingwaterataconcen-
tration of 35 mg/L [6, 18]. Placebo-treated animal groups were
given matched fodder with similar content of carbohydrates,
protein, and fat, and regular tap water was administered. All
animal groups had free access to rat chow and drinking water
throughouttheexperiment.Nitrendipine-containingfodderwas
coveredbymetalplatestoavoidlightexposure,andfodderwas
changed every 2nd or 3rd day. Enalapril-containing water was
changed every other day. Throughout the experiment, animals
were weighed, food consumption was measured, and tail-vein
blood glucose levels were determined by Haemoglucotest 1–
44 and Reﬂolux II reﬂectance meter (Boehringer-Mannheim,
Mannheim, Germany). Urinalysis was performed by simple
dip-sticks for glucose and ketones (Neostix-4, Ames, Stoke
Poges, Slough, UK). Three times during the study, all animals
were placed in metabolic cages for 24-hour urine collection
for determination of UAE (see below). Six control animals in
each intervention trial were taken out for investigation at the
beginning of the study as a reference group (CP0). Following
anesthesia with mebumal (50 mg/kg body weight, intraperi-
toneal [IP]), blood was drawn from the retro-orbital venous
plexus. Both kidneys were taken out and the capsules gently
removed. Kidneys were weighed, and the left kidney was ﬁxed
in3%formaldehydeand1%glutaraldehydeinmodiﬁedTyrode
buffer overnight [15, 16] for later morphometric analysis (see
below).
In the prevention trial (animal groups with sufﬁx “P”), 81
animals were included at study start, and 69 animals fulﬁlled
the study, n: CPP = 21 (6 animals investigated at study start,
CP0P), DPP = 10, DNP = 12, DEP = 14, DNEP = 12. Sim-
ilarly, in the intervention trial (animal groups with sufﬁx “I”),
76 animals were included with 44 animals fulﬁlling the study,
n: CPI = 14 (6 animals investigated at study start, CP0I),
DPI = 9,DNI = 7,DEI = 8,DNEI = 6.Theexclusioncriteria
were persistent ketonuria and weight loss, blood glucose levels
below 18 mmol/L, glucosuria below 111 mmol/L, death, or the
ﬁnding of pyelonephritis at study termination. Only data from
animals fulﬁlling these study criteria were included.
Blood Pressure Measurements
Bytheendofeachtreatmenttrial,systolicBPwasmeasured
in6to7randomlyselectedanimalsineachgroupbythetailcuff
method as previously described [19]. All measurements were
performed in the early afternoon to avoid 24-hour BP ﬂuctu-
ations. Animals were placed in an acrylic container, and after
approximately10minutes’acclimatization,5consecutivemea-
surements were performed, and a mean value was determined.
Urinary Albumin Excretion
Twenty-four-hourUAEwasdeterminedbyradioimmunoas-
say as previously described [20], using rat antibody and stan-
dards. Urine samples were stored at −20◦C until analysis.
Rabbit anti-rat albumin antibody (RAR/Alb) was purchased
from Nordic Pharmaceuticals and Diagnostics (Tilburg, The
Netherlands). For standard and iodination, a globulin-free rat
albumin was obtained from Sigma Chemicals.
Serum Fructosamine
Reagents and standards for the fructosamine assay, Fruc-
tosamine Test Plus, were purchased from Hoffmann-La Roche
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previouslydescribed[21].Serumsampleswerestoredat−20◦C
until assayed.
Kidney Morphology
Afterovernightﬁxation,theleftkidneywascutintoslicesof
2-mm thickness by a set of ﬁxed razor blades. The slices were
embedded in parafﬁn and sections were cut at 2 levels with a
distance of 250 µm and stained with the periodic acid–Schiff
reaction. This procedure provides a set of independently posi-
tionedsections,whichwereusedformeasurementsbystandard
stereological methods [15, 16, 22] using point counting for de-
termination of glomerular volume fraction. A grid with coarse
points:ﬁne points 1:4 was used. All sections were counted
blinded by the same observer. Total glomerular volume was
estimated as the product of volume fraction and kidney weight,
assuming that 1 mg kidney tissue equals 1 mm3.
Statistical Analyses
Differences between normally distributed data were com-
pared among groups by analysis of variance (ANOVA), and
TABLE 1
Body weight (g), serum fructosamine (µmol/L), and systolic blood pressure (mm Hg) in prevention
and intervention trials
A. Prevention trial (9 weeks)
Body weight Serum fructosamine
Animal group Day 0 9 weeks Day 0 9 weeks
Blood
pressure
9 weeks
CPP (n = 15) 199 ± 2 250 ± 5∗ 218 ± 5 216 ± 6# 110 ± 1
DPP (n = 10) 199 ± 6 229 ± 7 274 ± 11 112 ± 1
DNP (n = 12) 197 ± 4 219 ± 4 280 ± 7 112 ± 1
DEP (n = 14) 203 ± 8 214 ± 5 292 ± 10 97 ± 1†
DNEP (n = 12) 201 ± 4 222 ± 4 292 ± 59 7 ± 1†
B. Intervention trial (3 months and 7 weeks)
Body weight Serum fructosamine
Animal group Day 0 3 mo + 7 wk Day 0 3 mo + 7w k
Blood
pressure
3m o+ 7w k
CPI (n = 8) 211 ± 2 255 ± 4∗∗ 224 ± 4 221 ± 6## 97 ± 4
DPI (n = 9) 200 ± 2 223 ± 4 308 ± 10 106 ± 4
DNI (n = 7) 195 ± 2 226 ± 10 303 ± 10 112 ± 3
DEI (n = 8) 204 ± 4 232 ± 5 287 ± 79 4 ± 3
DNEI (n = 6) 201 ± 3 235 ± 7 319 ± 11 102 ± 2
CPP/CPI: nondiabetic control placebo-treated rats; DPP/DPI: diabetic placebo-treated rats; DNP/DNI: diabetic
nitrendipine-treated rats; DEP/DEI: diabetic enalapril-treated rats; DNEP/DNEI: diabetic nitrendipine/enalapril-
treated rats. Values are expressed as mean ± SEM.
∗P <. 05, CPP versus diabetic animals in the prevention trial.
#P <. 001, CPP versus diabetic animals in the prevention trial.
†P <. 05, DEP and DNEP versus DPP.
∗∗P <. 05, CPI versus diabetic animals in the intervention trial.
##P <. 01, CPI versus diabetic animals in the intervention trial.
when a signiﬁcant effect was identiﬁed, an unpaired t test
was performed. The values of UAE were logarithmically trans-
formed due to their positively skewed distribution. A P value
≤.05 in a 2-tailed test was considered indicative of a statisti-
callysigniﬁcantdifference.Onlydatawithinthesametrialwere
compared. All values are given as mean ± standard error of the
mean (SEM). When multiple comparisons were performed, the
Bonferroni correction was used.
RESULTS
Body Weight and Food Consumption
Body weights at study termination are shown in Table 1.
Although body weight was steadily increasing in nondiabetic
control animals, a marked growth retardation was observed
in all diabetic animal groups with lesser increase compared
to nondiabetic animals (P <.05). This growth retardation was
observed in both the prevention (Table 1A) and the interven-
tion (Table 1B) trials. However, no signiﬁcant difference was
seen between any of the diabetic groups in the two treatment
arms, indicating that neither nitrendipine nor enalapril showed194 B. NIELSEN ET AL.
any impact on body weight. Also, the number of animals ex-
cluded during the study was comparable between treated and
nontreated diabetic groups, although more animals assigned to
the intervention trial were excluded, probably due to severe hy-
perglycemiaforaprolongedperiodoftime.Diabeticanimalsre-
vealed hyperphagia 1 week after diabetes induction when com-
pared to nondiabetic animals, but no signiﬁcant difference in
food consumption was observed between treated or nontreated
diabetic animals. Daily food intake in all diabetic animals av-
eraged 28 ± 2 g/24 hours throughout the experiments, whereas
food intake in nondiabetic animals averaged 16 ± 2 g/24 hours
(data not shown). Thus, because all rat chows were matched,
no signiﬁcant difference in protein intake was observed be-
tweendiabeticrats.Finally,alldiabeticratsdevelopedpolydip-
sia, but the exact water consumption was not measured in these
studies.
Metabolic Parameters
Blood Glucose
Within 24 hours after STZ injections, diabetic animals were
hyperglycemic, with blood glucose levels averaging 25 ± 0.5
mmol/L.Allgroupsstabilizedatthislevelthroughoutthestudy,
and antihypertensive treatment showed no inﬂuence on blood
glucose. Blood glucose in nondiabetic animals averaged 4.6 ±
0.3 mmol/L (data not shown).
Serum Fructosamine
Fructosamine was assayed when terminating the trials, and
is shown in Table 1. All diabetic groups showed signiﬁcantly
increasedserumfructosaminecomparedtonondiabeticanimals
(P <.001), but no difference was detected among diabetic
groups, showing that neither treatment had any inﬂuence on
serum fructosamine.
Blood Pressure
Systolic BP measured by the end of the observation periods
isshowninTable1.Inthepreventiontrial,thediabeticstatedid
not lead to increased systemic BP in placebo treated animals
after 9 weeks (Table 1A). However, enalapril-treatment signiﬁ-
cantly reduced BP compared to placebo treatment (P <. 001),
whereas no further reduction in BP was detected when com-
bining enalapril and nitrendipine. When nitrendipine was ad-
ministered as monotherapy, no signiﬁcant reduction in BP was
observed compared to placebo-treated diabetic animals. Thus,
only enalapril led to a reduction in systemic BP, although all
animals were normotensive when the study was terminated.
In the intervention trial, no signiﬁcant difference in BP was
observed between nondiabetic and any of the diabetic groups
(Table 1B). Although enalapril treatment as monotherapy
and in combination with nitrendipine reduced systemic BP
in the prevention trial, this reduction was not observed in the
intervention trial.
Kidney Weight
Figure 1 shows kidney weight in non-diabetic animals at
study start (CP0), and in all other groups at study termination
in the prevention (Figure 1A) and the intervention trials
(Figure 1B). Diabetes induction was followed by highly sig-
niﬁcant renal hypertrophy compared to the nondiabetic con-
dition (P <.001). No signiﬁcant difference in kidney weight
was observed between placebo-treated diabetic animals and di-
abetic animals assigned to any of the antihypertensive treat-
ment regimens (P >.05) in neither prevention nor intervention
trials.
Glomerular Volume
Total glomerular volumes (TGV) are illustrated in Figure 2.
In both the prevention (Figure 2A) and the intervention
(Figure 2B) trials, diabetes was associated with a signiﬁ-
cant increase in TGV compared to the nondiabetic condition
(P <.05), and neither monotherapy nor combined treatment
withnitrendipineandenalaprilshowedanyimpactondiabetes-
inducedglomerularhypertrophycomparedtoplacebotreatment
(P >.05).
Urinary Albumin Excretion
Inthepreventiontrial,UAEwasmeasured3timesduringthe
study period and is presented in Figure 3A. One month follow-
ingdiabetesinduction,alldiabeticanimalsshowedasigniﬁcant
increase in UAE compared to nondiabetic animals (P <.05).
AlthoughUAEwaslowerintreatedanimalgroupsafter1month
comparedtoplacebo-treateddiabeticanimals,thisdidnotreach
statisticalsigniﬁcance(Figure3A).After9weeks,UAEwasre-
duced to the nondiabetic level in nitrendipine-treated rats, and
was signiﬁcantly different from placebo-treated diabetic ani-
mals(P <.05).Combiningenalaprilandnitrendipinetreatment
showednofurtherreductioninUAEcomparedtomonotherapy
with nitrendipine, and monotherapy with enalapril failed to re-
vealasigniﬁcantreductioninUAEcomparedtoplacebo-treated
diabetic animals, although a tendency toward a lower UAE was
observed (P >.05).
Intheinterventiontrial,ahighlysigniﬁcantincreaseinUAE
was observed after 3 months of untreated diabetes compared to
the nondiabetic condition (P <.001) (Figure 3B). Following
7 weeks of treatment with nitrendipine and/or enalapril, only
nitrendipine and enalapril given in combination signiﬁcantly
reduced UAE compared to untreated diabetic animals (P <
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FIGURE 1
Right kidney weights in all animal groups are illustrated in mg. Prevention trial (A) and intervention trial (B). CP0P/CP0I:
nondiabetic control placebo-treated rats at study start; CPP/CPI: nondiabetic control placebo-treated rats at end of study;
DPP/DPI: diabetic placebo-treated rats; DNP/DNI: diabetic nitrendipine-treated; DEP/DEI: diabetic enalapril-treated;
DNEP/DNEI: diabetic nitrendipine/enalapril-treated. Values are shown as mean ± SEM. ∗P <. 001, CPP versus diabetic animal
groups in the prevention trial. ∗∗P <. 001, CPI versus diabetic animal groups in the intervention trial.
FIGURE 2
Total glomerular volume in the prevention trial (A) and the intervention trial (B). CP0P/CP0I: nondiabetic control placebo-treated
rats at study start; CPP/CPI: nondiabetic control placebo-treated rats at end of study; DPP/DPI: diabetic placebo-treated rats;
DNP/DNI: diabetic nitrendipine-treated; DEP/DEI: diabetic enalapril-treated; DNEP/DNEI: diabetic
nitrendipine/enalapril-treated. Values are shown as mean ± SEM. ∗P <. 05, CP0P versus CPP; #P <. 05, CPP versus DPP;
∗∗P <. 05, CP0I and CPI versus DPI.196 B. NIELSEN ET AL.
FIGURE 3
Urinary albumin excretion shown on a logarithmic scale. Prevention trial (A) and intervention trial (B). CPP/CPI: nondiabetic
control placebo-treated rats at end of study; DPP/DPI: diabetic placebo-treated rats; DNP/DNI: diabetic nitrendipine-treated;
DEP/DEI: diabetic enalapril-treated; DNEP/DNEI: diabetic nitrendipine/enalapril-treated. Values are shown as mean ± SEM.
∗P <. 05, DNP and DNEP versus DPP; #P <. 05, DNEI versus DPI.
failed to reduce UAE signiﬁcantly after 3 months of untreated
diabetes (Figure 3B).
DISCUSSION
Inthepresentstudy,weinvestigatedwhetherCCBtreatment
was as effective as ACEI treatment in preventing the develop-
mentofdiabetickidneydiseaseinSTZdiabeticWistarrats.The
importanceoftimeofinterventionwasinvestigatedbycompar-
ingpreventionandintervention.Also,apotentialadditiveeffect
of combining the 2 treatment arms was investigated.
We found that monotherapy with the dihydropyridine CCB
nitrendipine reduced the diabetes-associated increase in UAE
when starting treatment right at the time of diabetes induction
(prevention), whereas no such effect was observed with the
ACEIenalapril,despitethatalowerBPwasattainedwithACEI
treatment. Postponing treatment until diabetic renal changes
were manifest after 3 months of untreated diabetes (interven-
tion),onlythecombinationofCCBandACEIwasabletoreduce
UAE, whereas no such effect was observed by either treatment
alone. These results were observed without any inﬂuence on
metabolic control and renal or glomerular hypertrophy. The
results obtained with nitrendipine treatment alone are in accor-
dance with our previous studies [15, 16, 22] reporting nitrendi-
pine to reduce UAE in diabetic rats, when starting treatment
early in the disease, without a signiﬁcant effect on kidney size
and glomerular hypertrophy [16, 22]. In the present study, BP
was only signiﬁcantly lowered in animal groups treated with
ACEI or ACEI/CCB in the prevention trial. In the interven-
tion trial, BP was also lower in ACEI-treated animals, but due
to much greater variability in BP within the individual groups
after 3 months and 7 weeks, this did not reach statistical signif-
icance. We used the tail-cuff method for detecting systolic BP,
becausetheanimalsinthisstudywereseverelyhyperglycaemic,
and thus sensitive to invasive procedures. However, previous
studies have shown that antihypertensive treatment may abol-
ish the normal circadian rhythm of BP [23], which limits the
assessment of ambient systemic BP using the tail-cuff method,
although the diurnal variation was reduced by performing all
BP measurements during early afternoon. The BP-lowering ef-
fect of ACE inhibition and no effect on BP due to calcium
channel blockade have been reported previously in experimen-
tal studies in normotensive diabetic Wistar rats [6, 15, 16, 18,
22, 24].
Severalclinical[3,4,25–27]andexperimental[28–30]stud-
ies have shown that ACEI treatment is able to prevent or post-
pone the development of diabetic kidney disease, and ACEIs
havebecomethedrugsofﬁrstchoicewheninitiatingantihyper-
tensive treatment in microalbuminuric diabetic patients [31].
However, our present study failed to demonstrate any effect
of enalapril on diabetes-associated renal changes, i.e., renal
and glomerular hypertrophy and albuminuria, which is not ex-
plainedbyinsufﬁcientdrugdosage,becauseasigniﬁcantreduc-
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trialofthisstudy,onlythecombinationofCCBandACEItreat-
ment showed inhibitory effects on renal changes compared to
monotherapy with either drug, further indicating that enalapril
was given in a adequate dosage, and in accordance with previ-
ous studies [6, 18]. Thus, biologic variation and the relatively
large day-to-day variation in UAE, which was particular high
in the group in which enalapril was given as monotherapy, may
explain why no signiﬁcant effect was observed on UAE in this
group. Despite having 14 animals fulﬁll the study criteria in the
enalapril-treated group in the prevention trial, the great vari-
ability in UAE may have caused a statistical type II error. The
determination of UAE was performed by a well-described ra-
dioimmunoassay [20] and in accordance with previous studies
[6,14,15,22,24],thusthelackofaneffectonalbuminuriainthe
enalapril-treatedgroupisnotbelievedtobeduetomethodolog-
ical errors. However, it would have been warranted to collect
24-hour urine in a consecutive number of days to minimize the
variability. Despite the lack of an antialbuminuric effect ob-
served by enalapril treatment and the discrepancy with other
reports [6, 18], the results of the present study are important,
because CCB treatment was shown to be at least as effective
as ACEI treatment in slowing the progression of experimental
diabetic kidney disease, using UAE as an end-point parameter.
More importantly, it was demonstrated in the intervention trial
that in a more advanced state of diabetic kidney disease, only
thecombinationofACE-inhibitionandcalciumchannelblock-
ade achieved a reduction in UAE. Thus, despite the variability
in BP in the prevention and intervention trials, and the lack of
an antiproteinuric effect following enalapril treatment, the hy-
pothesis that ACEI and CCB treatments show additive effects
in the prevention of diabetic kidney disease was demonstrated.
Although UAE was lowered by nitrendipine in the prevention
trial, and by combination therapy in the intervention trial, no
effect on renal and glomerular hypertrophy was observed at
any time. Previous studies in experimental diabetes also report
lowering effects on UAE with unchanged renal enlargement
following CCB therapy [16] and ACEI treatment [30].
Several studies have investigated the effect of both dihy-
dropyridine and nondihydropyridine CCBs on the progression
ofdiabetickidneydisease.However,thestudiesareveryhetero-
geneous, investigating type 1 or type 2 diabetic patients with
either incipient or overt diabetic nephropathy, or in the case
of investigating STZ diabetic animals, using rats of different
species, or diabetic Beagle dogs; for review see [14]. Also, re-
sults are divergent and conﬂicting results and much attention
has been paid to the use and safety of CCBs in both type 1
and type 2 diabetic patients after the premature termination
of the ABCD trial [32] and the FACET study [33]. The supe-
rior effect of ACEIs compared to other antihypertensive drugs
has been ascribed a renoprotective effect, i.e., an effect that is
beyondtheeffectcausedbyareductioninsystemicBP.Studies
have reported an inhibition of diabetic renal changes irrespec-
tive of systemic BP reduction, indicating a direct effect on in-
trarenal hemodynamics [3–5, 27]. ACEIs have a dilating effect
on the glomerular efferent arteriole, and thus reduce the intra-
glomerular hydraulic pressure [34, 35], which may explain the
renoprotectiveeffectobservedwithoutaconcomitantreduction
in systemic BP. In contrast to ACEIs, CCBs intrarenal effect is
believed to be a dilating effect on the afferent more than on the
efferent arteriole [36, 37], and theoretically this should induce
an increase in glomerular capillary pressure. A renoprotective
effectisthusdependentonaconcomitantreductioninsystemic
BP. However, both ACEIs and CCB may possess nonvascular
effects. In vitro studies have shown that the mitogenic effect of
several growth factors are attenuated by both ACEIs [6, 30, 38]
and CCBs [39], and both groups of drugs have been reported
to preserve glomerular heparan sulfate [9, 40]. Thus, despite a
greater dilating effect on the afferent arteriole than on the effer-
entarterioleattainedbyCCBtreatment,thenonvasculareffects
couldbeveryimportant.Inrecentpapers,ithasbeensuggested
that BP reduction to a level of 125–130/80–85 mm Hg may be
more important than the actual drug chosen in the treatment of
diabeticpatients[41–44].ReducingBPtothislevelinhyperten-
sivepatients,diabeticaswellasnondiabeticsubjects,mayonly
be attainable with the combination of 2 or more antihyperten-
sivedrugs.BecauseACEIsreducethegenerationofangiotensin
II (AT-II), and CCBs reduce target-organ responsiveness to AT-
II [37, 45], these two groups of antihypertensive drugs may be
preferabletoconventionaltherapyindiabeticpatients,eitheras
monotherapy, or administered in combination.
In the present study, we demonstrated a BP reduction fol-
lowing monotherapy with enalapril, whereas no effect on UAE
was observed, thus, conﬁrming that diabetic kidney disease is
caused by other factors besides systemic BP. This was con-
solidated by the fact that nitrendipine lowered UAE compared
to enalapril treatment, despite that nitrendipine-treated animals
showed a signiﬁcantly higher BP than enalapril-treated ani-
mals. Also, no difference in metabolic parameters between the
different trials was observed. However, potential nonvascular
mechanisms were not investigated in this study.
It has been claimed in several papers by Bakris and col-
leagues that only nondihydropyridine CCBs show a protection
against diabetic renal disease [10, 12, 46–48]. However, only 1
long-termclinicalstudyfromanothergrouphasinvestigatedthe
effectofadihydropyridineCCB,namelynisoldipine,andfound
CCB treatment to preserve glomerular ﬁltration rate (GFR) to
the same extent as ACEI (lisinopril) treatment, despite a bet-
ter antiproteinuric effect observed with lisinopril over a 4-year
study period [11]. As stated in this article [11], GFR is a better
end-point parameter than UAE when evaluating renal function.198 B. NIELSEN ET AL.
Thus,becausethegoalofBPreductionindiabeticpatientsmay
not be attainable with monotherapy with ACEI, the results of
the present study and the study mentioned above [11] indicate
that the combination of dihydropyridine CCB and ACEI treat-
ment may be a potential treatment of diabetic patients with
hypertension with or without nephropathy.
In conclusion, the dihydropyridine CCB nitrendipine atten-
uates the development of albuminuria in normotensive diabetic
rats without a reduction in systemic BP when starting treat-
ment at diabetes debut. If postponing treatment until renal
changes are present, only the combination of a CCB and an
ACEI shows a reduction in UAE compared to either treatment
alone. The impact of combination therapy on both hemody-
namic and nonhemodynamic parameters needs further investi-
gation in clinical as well as experimental studies.
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